OncoMatch

OncoMatch/Clinical Trials/NCT06373211

Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

Is NCT06373211 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Immunoglobulins IV (CLAYRIG) and Cyclophosphamide IV for paraneoplastic sensory neuronopathy.

Phase 2RecruitingAssistance Publique - Hôpitaux de ParisNCT06373211Data as of May 2026

Treatment: Immunoglobulins IV (CLAYRIG) · Cyclophosphamide IV · Methylprednisolone IVParaneoplastic Neurological Syndromes are rare autoimmune complications linked to the presence of systemic cancer. Despite their autoimmune origin, they have historically shown little response to immunotherapy. The reason for this failure is probably related to too late administration of immunotherapy, at a stage where the inflammation has already disappeared and irreversible neuronal loss has occurred. The protocol focuses on patients with anti-Hu antibody sensory neuronopathy. This single arm trial consists of an early immunotherapy combining Intravenous Immunoglobulin (IVIG) for 3 months, cyclophosphamide and methylprednisolone for 6 months, at the rate of 1 cycle per month. The percentage of patients with clinical improvement will be evaluated (ONLS) at 3 months. The tolerance of the treatment will also be evaluated as well as other functional scales at 3 and 6 months.

Check if I qualify

Extracted eligibility criteria

Performance status

MODIFIED RANKIN SCORE 2–3

Prior therapy

Cannot have received: IVIg

More than two courses of IVIg administered within 3 months before recruitment

Cannot have received: immunotherapy

Other concomitant immunotherapy

Cannot have received: checkpoint inhibitor

Treatment with checkpoint inhibitors in progress or completed less than 3 months previously

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify